SUPPLEMENTARY PROSPECTUS DATED 13 SEPTEMBER 2023



LLOYDS BANK CORPORATE MARKETS plc

(incorporated in England with limited liability with registered number 10399850)

£10,000,000,000

Euro Medium Term Note Programme

This Supplement (the "**Supplement**") to the prospectus dated 30 June 2023 which comprises a base prospectus (the "**Prospectus**") for the purposes of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "**UK Prospectus Regulation**"), constitutes a supplementary prospectus for the purposes of Article 23 of the UK Prospectus Regulation, and is prepared in connection with the £10,000,000,000 Euro Medium Term Note Programme (the "**Programme**") established by Lloyds Bank Corporate Markets plc (the "**Issuer**").

This Supplement is supplemental to, and should be read in conjunction with, the Prospectus and the documents incorporated by reference therein. Capitalised terms used in this Supplement but not defined herein shall have the meanings ascribed to them in the Prospectus.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Purpose of this Supplement

The purpose of this Supplement is to:

- (a) incorporate by reference into the Prospectus the Issuer's 2023 Half-Year Results (as defined in this Supplement), which was published via the RNS on 13 September 2023; and
- (b) update the no significant change statement of the Issuer and its subsidiary and associated undertakings (the "LBCM Group").

(a) Documents Incorporated by Reference

By virtue of this Supplement, the Issuer's half-year results for the half-year to 30 June 2023, including the unaudited condensed consolidated half-year financial statements for the half-year to 30 June 2023, together with the independent review report thereon, as set out on pages 10 to 39 and pages 41 to 42, respectively (the "2023 Half-Year Results"), which was published by the Issuer via RNS on 13 September 2023 (RNS Number 3040M) and available at https://www.lloydsbankinggroup.com/assets/pdfs/investors/financial-performance/lloyds-bank-corporate-markets-plc/2023/q2/2023-lbcm-hy-results.pdf and which has previously been filed with the Financial Conduct Authority shall be deemed to be incorporated in, and form part of, the Prospectus and supplement the section entitled "Documents Incorporated by Reference" on pages 12 to 13 of the Prospectus.

Any documents themselves incorporated by reference in the 2023 Half-Year Results shall not form part of the Prospectus, unless specified otherwise here.

(b) No significant change of the LBCM Group

The no significant change of the LBCM Group statement at paragraph 3 on page 182 of the Prospectus shall be deleted in its entirety and replaced as set out below:

There has been no significant change in the financial position or financial performance of the LBCM Group since 30 June 2023, the date to which the LBCM Group's last published unaudited interim financial information (as set out in the Issuer's 2023 Half-Year Results) was prepared.

The Issuer will provide, without charge, to each person to whom a copy of this Supplement has been delivered, upon the oral or written request of such person, a copy of any or all of the documents which are incorporated in whole or in part by reference herein or in the Prospectus. Written or oral requests for such documents should be directed to the Issuer at its principal office at 25 Gresham Street, London EC2V 7HN. Copies of all documents incorporated by reference in this Supplement can also be viewed on the website of the Regulatory News Service operated by the London Stock Exchange at: https://www.londonstockexchange.com/news?tab=news-explorer.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in or incorporated by reference into the Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement, no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus has arisen or been noted, as the case may be, since the publication of the Prospectus.